Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;9(3):963-971.
doi: 10.1007/s13300-018-0404-6. Epub 2018 Mar 21.

The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis

Pan-Wei Mu  1 , De-Zhao Liu  2 , Ying Lin  3 , Dong Liu  4 , Fan Zhang  1 , Yong-Jun Zhang  4 , Shuo Lin  1 , Lin-Qin Wang  5 , Man-Man Wang  1 , Jiong Shu  1 , Long-Yi Zeng  1 , Yan-Ming Chen  6
Affiliations

The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis

Pan-Wei Mu et al. Diabetes Ther. 2018 Jun.

Abstract

Introduction: Basal insulin is widely recommended for the treatment of type 2 diabetes mellitus (T2DM) patients who are unable to achieve glycemic control with oral antidiabetic drug(s) (OADs). However, some patients are still unable to control their blood glucose levels even when on basal insulin-supported OAD(s) therapy (BOT). The aim of this study was to investigate the factor(s) predicting patient response to BOT.

Methods: A total of 212 patients with T2DM, ranging in age from 18 to 65 years, admitted to the university hospital of Sun Yat-sen University, Guangzhou, China, were enrolled in the study between January 2013 and July 2016. All patients had fasting blood glucose levels of ≥ 10.0 mmol/L despite receiving OAD(s) treatment. According to study design, these patients first received intensive insulin therapy for 2 weeks to attain and maintain their glycemic goals and then were switched to BOT. Responders were defined as subjects who maintained their glycemic targets with BOT for at least 3 months; all others were considered to be non-responders. The characteristics between responders and non-responders were compared.

Results: Compared with non-responders, responders had a shorter duration of diabetes (5.1 ± 5.0 vs. and 10.1 ± 3.2 years; P < 0.001) and a higher 2-h postprandial C-peptide-to-fasting C-peptide ratio (2 h-PCP/FCP: 1.95 ± 0.51 vs. 1.67 ± 0.32; P < 0.01). Responders showed a lower proportion of previous treatment with insulin (69/100 vs 40/3; P < 0.001) and sulfonlureas or glinides (116/50 vs 40/0; P <0.001) than non-responders. Multivariate logistic regression analysis showed that previous insulin treatment (odds ratio [OR] 17.677, 95% confidence interval [CI] 5.205-60.027; P < 0.001) and the 2 h-PCP/FCP ratio (OR 0.241, 95% CI 0.058-0.679; P = 0.007) had predictive value.

Conclusions: A higher 2 h-PCP/FCP ratio and a lack of previous insulin treatment increase the likelihood of BOT success.

Keywords: Basal insulin; C-peptide; Predictor; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of patient selection and treatment. BOT Basal insulin-supported oral antidiabetic drug(s) therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1–68. doi: 10.4158/EP.13.S1.1. - DOI - PubMed
    1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025. - DOI - PMC - PubMed
    1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract. 2013;19:536–557. doi: 10.4158/EP13176.CS. - DOI - PMC - PubMed
    1. Lavernia F. What options are available when considering starting insulin: premix or basal? Diabetes Technol Ther. 2011;13(Suppl 1):S85–S92. doi: 10.1089/dia.2010.0248. - DOI - PubMed
    1. Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr TA, et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin. 2010;26:1621–1628. doi: 10.1185/03007995.2010.485087. - DOI - PubMed

LinkOut - more resources